The impact of the exodus of big pharmaceutical companies from Nigeria on antimicrobial resistance in the West African subregion

Chiamaka Norah Ezeagu; Semeeh Akinwale Omoleke; Kehinde Kazeem Kanmodi

doi:10.1186/s44263-024-00068-z

The impact of the exodus of big pharmaceutical companies from Nigeria on antimicrobial resistance in the West African subregion

BMC Glob Public Health. 2024 May 24;2(1):35. doi: 10.1186/s44263-024-00068-z.

Authors

Chiamaka Norah Ezeagu^{1

2}, Semeeh Akinwale Omoleke³, Kehinde Kazeem Kanmodi^{1

2

4

5}

Affiliations

¹ School of Health and Life Sciences, Teesside University, Middlesbrough, UK.
² Cephas Health Research Initiative Inc, Ibadan, Nigeria.
³ The Engelhardt School of Global Health and Bioethics, Central African Republic and The Gambia, Euclid University (EUCLID), Banjul, Gambia. [email protected].
⁴ School of Dentistry, University of Rwanda, Kigali, Rwanda.
⁵ Faculty of Dentistry, University of Puthisastra, Phnom Penh, Cambodia.

Abstract

The departure of pharmaceutical companies from Nigeria - a major source of antimicrobial drug supply in West Africa - increases the risk of an elevated burden of antimicrobial resistance (AMR) in Nigeria and the West Africa subregion. Urgent actions must be taken by relevant actors to address the increased risk of AMR.

Publication types

Letter